Navigation Links
Small Change Could Stop Epilepsy Seizures for Millions

Medicine costing less than three dollars a year per patient could spare 30 millions poor people, many of them children, from the trauma and torment of epilepsy, a new study released Friday has found .

Some 85 percent of epilepsy sufferers in the developing world go without any treatment whatsoever because they cannot afford the drugs most often prescribed to impede the terrible seizures associated with the illness.

The least expensive of these medications, phenobarbital, has been recommended by the World Health Organization (WHO) for victims of convulsive seizures in poor countries, but has been otherwise shunned because it is thought to have more serious side-effects, especially on children.

A drug trial of 108 children in Bangladesh, however, comparing phenobarbital with carbamazepine -- commonly prescribed for epilepsy -- showed the less expensive drug to be equally effective. The study, led by paediatric neurophysiologist Selina Banu and to be published in the British Medical Journal, also concluded it did not provoke more behavioural problems, such as hyperactivity and restlessness.

A follow-up study a year later confirmed the initial findings. Carbamazepine, sold in generic form, retails for about 700 dollars (520 euros) at adult doses for a year's treatment, compared to less than three dollars for phenobarbital. "The burden of untreated epilepsy in terms of human suffering and social costs is enormous," the British Medical Journal said in an accompanying editorial.

"Governments and non-governmental organizations in developing countries need to ensure that effective treatment is effective for all." Epilepsy victims, especially children, are often stigmatized because of unpredictable and violent seizures that can be highly disruptive in daily life.

In some cases major attacks resulting in status epilepticus -- a condition in which seizures last for more than 30 minutes or follow in rapid succession -- require hospitalization.

The researchers cautioned that the conditions of the drug trial, carried out at the Children's Hospital in Dhaka, Bangladesh, were not ideal.

Some children dropped out of the follow up studies and there was a sex-ratio imbalance for one of the drug groups. But even with these shortcomings, the study showed that most children tolerated phenobarbital well and behaviour even improved in many, they reported.


'"/>




Related medicine news :

1. Smallpox as Biological Weapons?
2. Is Smallpox Threat Real ?
3. Smallpox Vaccine May Help Fight Cervical Cancer
4. Smallpox Would Spread Rapidly
5. Drug Firm Offers to Donate Smallpox Vaccine
6. Small aneurysms best left untouched
7. Small lumps in breast if not treated may cause long-term harm
8. Third generation Small pox vaccine from Cell-culture
9. CT Scans Said to Accurately Detect Small Cancers
10. Brain of Cocaine Addicts Smaller In Size
11. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/20/2017)... ... February 20, 2017 , ... ... self-service technology that runs on the Posiflex XT-series of touch screen terminals. Both ... HIMSS17 in Orlando, Florida. The terminal provider Posiflex is helping to bridge ...
(Date:2/20/2017)... , ... February 20, 2017 , ... ... welcomes you to stop by for a visit this week at HIMSS 2017 ... and executives from around the globe. Sensogram will be featured in the conference’s ...
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
(Date:2/20/2017)... Orlando, FL (PRWEB) , ... February 20, 2017 ... ... company for eye care providers and health plan partners, announced during the 2017 ... the organization’s success enhancing care coordination for diabetic patients and integrating eye ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... Braun Industries ... JEMS Conference & Exposition, the event will take place February 23-25, 2017 at the ... will be in Booth #909 with three new ambulances on display. ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017   FormFast , ... announced a new partnership with Engage , one ... United States . FormFast will serve as the ... Engage,s implementations with MEDITECH .  ... essential functionality to complement and enhance the electronic health ...
(Date:2/17/2017)...  BioDigital, Inc., creators of the BioDigital Human ... body mapping technology with eClinicalWorks, a privately held ... be used to capture and present dermatology exam ... body. BioDigital pilots show using a body to ... the precision of clinical annotations compared to standard ...
(Date:2/17/2017)... YORK , Feb. 17, 2017  Noble Capital ... on ESSA Pharma Inc. (Nasdaq: EPIX ). ... Research, Kumar Raja , PhD. ESSA ... for castration resistant prostate cancer (CRPC). Its lead compound ... blocks the amino-terminal domain of the androgen receptor, thereby ...
Breaking Medicine Technology: